Dear Colleagues:
Multinational clinical trials are becoming increasingly common, with bio-pharmaceutical companies often conducting trials at multiple sites and in several different countries. As a result, manufacturing labels and inserts for investigational medicinal products (IMPs) must commonly be translated into multiple languages in accordance with country-specific regulations. Moreover, successful completion of a clinical study as well as patient safety largely depend on adherence to the study protocol.This means that clinical trial supplies must be provided in clear and accurate language that will be well understood by the patient.
Our life sciences expert has written a white paper which discusses how language barriers must be addressed by drug manufacturers and distributors in global clinical trials. What are the regulatory and translation requirements for IMP labels in countries conducting clinical trials? What challenges do drug manufacturers face in providing multilingual labels?
Please take this opportunity to read our white paper available via the following link . We hope that it provides you with useful information.
As a language service provider for over fifteen years, we are well aware of the importance of accurate, quality translation, especially in the translation of clinical trial documents. Our life science experts have translation experience in over one hundred languages. Not only are they native speakers, they also know the importance of incorporating cultural context to produce high quality culturally adapted translations. |
Thank you for your time and interest. If you have any inquiries or comments regarding the article or our services, please do not hesitate to contact us or visit our website at www.languageconnections.com!
Kind Regards,
Leo Galperin, President
Language Connections
Boston, MA
Tel: 617-731-3510
www.languageconnections.com
Wherever you do business, we speak the language.
  
|
